Physician profile
Mark R Leone
NPI 1144295049
$6,984.56
in general payments reported to CMS, 2019-2025
22 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $387 · 2021: $1,205 · 2022: $1,462 · 2023: $502 · 2024: $489 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,588.40 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $885.78 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $713.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $490.91 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $465.63 | 2021-2023 | |
| Amgen INC. | $444.31 | 2019-2024 | Repatha, Krystexxa |
| Kowa Pharmaceuticals America, INC. | $439.30 | 2019-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.98 | 2019-2023 | Jardiance, Trijardy Xr, Tradjenta |
| Janssen Pharmaceuticals, INC | $379.16 | 2019 | |
| Lilly USA, LLC | $258.60 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $209.77 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $168.59 | 2019-2023 | Ajovy |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Allergan, INC. | $113.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.94 | 2019-2023 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.34 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.38 | 2023 | Xifaxan |
| Pfizer INC. | $26.82 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $26.66 | 2021 | |
| Abbott Laboratories | $23.70 | 2022 | |
| Bausch Health US, LLC | $15.00 | 2022 | |
| Sanofi Pasteur INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.